Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00631449 · ClinicalTrials.gov registry record · Phase 4
Raltegravir Intensification in HIV-infected Patients
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT00631449 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 30 participants.
The verdict
NCT00631449, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
Interventions
- DRUG Placebo
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-02 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00631449
The ClinicalTrials.gov registry entry for NCT00631449 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00631449 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00631449 about?
NCT00631449 is a clinical study titled "Raltegravir Intensification in HIV-infected Patients". The purpose of this study is to determine whether treatment with Raltegravir further decreases HIV viral replication in HAART-suppressed, HIV-infected patients, potentially improving immune response to antiretroviral therapy.
What is the current status of trial NCT00631449?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-02. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00631449?
The interventions under investigation include: Placebo (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT00631449?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.